The Medicines Company
8 Sylvan Way
Parsippany
New Jersey
07054
United States
Tel: 973-290-6000
Fax: 973-656-9898
Website: http://www.themedicinescompany.com/
Email: contactus@themedco.com
About The Medicines Company
The Medicines Company's purpose is to save lives, alleviate suffering and contribute to the economics of healthcare by focusing on 3,000 leading acute/intensive care hospitals worldwide. Its vision is to be a leading provider of solutions in three areas: acute cardiovascular care, surgery and perioperative care, and serious infectious disease care. The company operates in the Americas, Europe and the Middle East, and Asia Pacific regions with global centers today in Parsippany, NJ, USA and Zurich, Switzerland.
501 articles about The Medicines Company
-
The Medicines Company To Present At The 25th Annual JP Morgan Healthcare Conference
1/3/2007
-
The New England Journal of Medicine Publishes The Medicines Company's Angiomax(R) (Bivalirudin) ACUITY Trial Results
11/27/2006
-
The Medicines Company To Present At The Annual 2006 Stanford Growth Conference
11/8/2006
-
The Medicines Company Reports Third Quarter 2006 Financial Results
10/25/2006
-
The Medicines Company To Announce Third Quarter 2006 Financial Results On Wednesday, October 25, 2006
10/11/2006
-
The Medicines Company Commences Phase III Clinical Trial Of Cangrelor
10/4/2006
-
The Medicines Company Completes Clevidipine Phase III Safety Trials And Initiates Phase III Severe Hypertension Trial; ECLIPSE Enrollment Complete, First Patient Enrolled In VELOCITY
9/11/2006
-
The Medicines Company To Present At Bear Stearns And UBS Conferences
9/6/2006
-
The Medicines Company Reports Second Quarter And First Half 2006 Financial Results
7/25/2006
-
The Medicines Company To Announce Second Quarter 2006 Financial Results On Tuesday, July 25, 2006
7/13/2006
-
The Medicines Company Reports First Quarter 2006 Financial Results
4/19/2006
-
The Medicines Company To Announce First Quarter 2006 Financial Results On Wednesday, April 19, 2006
4/13/2006
-
The Medicines Company Commences Patient Enrollment In Pivotal Phase III Clinical Trial Of Cangrelor
4/4/2006
-
The Medicines Company Release: Angiomax(R) Monotherapy Superior To Heparins Plus GP IIb/IIIa Combination For Net Clinical Outcome In ACUITY Trial
3/13/2006
-
The Medicines Company Announces Glenn Sblendorio To Be New Chief Financial Officer
3/6/2006
-
The Medicines Company Reports Fourth Quarter And Full Year 2005 Financial Results
2/15/2006
-
The Medicines Company To Announce Fourth Quarter And Full Year 2005 Financial Results On Wednesday, February 15, 2006
2/9/2006
-
The Medicines Company To Present At The 24th Annual JP Morgan Healthcare Conference
1/4/2006
-
The Medicines Company Completes Enrollment Of 13,800-Patient ACUITY Trial Of Angiomax(R) (bivalirudin)
12/7/2005
-
FDA Approves Expansion Of The Medicines Company's Angiomax(R) Label To Include Patients With Or At Risk Of HIT/HITTS Undergoing PCI; HIT/HITTS Places Patients At Higher Risk Of Life-Threatening Complications
12/1/2005